Recent Quotes (30 days)

You have no recent quotes
chg | %

Critical Outcome Technologies Inc.  

(Public, CVE:COT)   Watch this stock  
Find more results for COT
0.240
-0.005 (-2.04%)
Delayed:   10:04AM EST
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.24 - 0.25
52 week 0.14 - 0.37
Open 0.25
Vol / Avg. 9,500.00/28,974.00
Mkt cap 27.35M
P/E     -
Div/yield     -
EPS -0.04
Shares 113.95M
Beta 0.00
Inst. own     -
Nov 12, 2014
Critical Outcome Technologies Inc at SeeThruEquity Microcap Investor Forum
Nov 5, 2014
Critical Outcome Technologies Inc at EBD Group BIO-Europe Conference
Oct 7, 2014
Critical Outcome Technologies Inc at BIO Investor Forum
  

Key stats and ratios

Q4 (Oct '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -152.76% -125.25%
Return on average equity -233.20% -177.54%
Employees 10 -
CDP Score - -

Address

Suite 213, 700 Collip Circle
LONDON, ON N6G 4X8
Canada
+1-519-8585157 (Phone)
+1-519-8585179 (Fax)

Website links

Description

Critical Outcome Technologies Inc. (COTI) is a biotechnology company focused on applying its computer-based technology, CHEMSAS, to identify, profile, optimize and select potential new drug candidates at the discovery stage of preclinical drug development. COTI is concentrated on developing drug candidates for the treatment of various cancers, human immunodeficiency virus (HIV), Alzheimer�s disease and multiple sclerosis. Cancer types specifically targeted include small cell lung cancer, adult myelogenous leukemia (AML), ovarian, endometrial, pancreatic, brain, breast and colorectal cancer. COTI 2 is a advanced compound in COTI�s drug development pipeline. COTI-2 is a novel small molecule that acts by inhibiting Akt/PKB (Protein kinase B) phosphorylation that leads to caspase-9 activation in cancer cells resulting in tumor cell death. In February 2012, the Company announced the development of 8 oral formulation candidates for COTI2 as potential Phase 1 oral formulations.

Officers and directors

John C. Drake Independent Chairman of the Board
Wayne R. Danter M.D. President, Chief Executive Officer, Chief Scientific Officer, Director
Gene Kelly Chief Financial Officer
Douglas S. Alexander Independent Director
Bruno C. Maruzzo Independent Director
Age: 60
Dave Sanderson Independent Director